

ASX / MEDIA RELEASE

10 DECEMBER 2019

Appointment of Michael Daniell to the Cochlear Limited Board

Cochlear Limited today announced the appointment of Michael Daniell to the Cochlear Board. Mr Daniell's appointment will become effective on 1 January 2020.

Mr Daniell has worked in the medical device industry for 40 years and has extensive executive leadership experience. He was Managing Director and CEO of Fisher & Paykel Healthcare Corporation Limited ("Fisher & Paykel Healthcare") from November 2001 to March 2016. Mr Daniell was responsible for the global business and operations including the design, manufacture and marketing of innovative products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. Prior to this, Mr Daniell held various technical management and product design roles within Fisher & Paykel Healthcare.

Cochlear Chair, Rick Holliday-Smith, welcomed Mr Daniell's appointment. "Michael has a long and distinguished career in building a globally successful medical device company. His deep experience and expertise in product innovation and leveraging new technologies will be invaluable to the Board. We look forward to his contributions to the continued growth and strategic development of Cochlear."

Mr Daniell is currently a Non-Executive Director of Fisher & Paykel Healthcare. He is also a Council member of the University of Auckland and a Non-Executive Director of the Medical Research Commercialisation Fund in Melbourne, Australia.

Mr Daniell will be a Non-Executive Director and is considered by the Board to be independent. He resides in New Zealand.

Authorised by the Board of Directors, Cochlear Limited

For further information, please contact:

Analysts

Kristina Devon
Head of Investor Relations
Email: kdevon@cochlear.com
Ph: + 61 2 9611 6691

Media

Jennifer Stevenson
Head of Corporate Communications
Email: jstevenson@cochlear.com
Ph: +61 2 9611 6959